March 10, 2011 08:18 ET

Equity Research on Pfizer Inc. and Bristol-Myers Squibb Co. - Big Pharma Facing Big Problems

NEW YORK, NY--(Marketwire - March 10, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the drug manufacturers - major industry and are offering free analytical research on Pfizer Inc. (NYSE: PFE) and Bristol-Myers Squibb Co. (NYSE: BMY). Register with us today at to have free access to this research and speak to one of our pros.

Expiring patents could have some serious effects on revenues for large pharmaceutical companies this year and the next. The recent suspension of a couple vaccines in Japan is also causing problems for companies in the major drugs manufacturers' space. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future. is the Ultimate Trading Environment for investors. If you are considering owning Pfizer Inc. and Bristol-Myers Squibb Co. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Shine's performance in 2005 was +14%, 2006 + 26%, 2007 +99%, 2008 + 355% and 2009 + 46%. Sign up today to find out what you are missing. 

Pfizer Inc.'s patent on blockbuster drug Lipitor expires this year. Pfizer does have a deal in place with an Indian pharmaceutical company though, which has 180 days of exclusivity for atorvastatin in the U.S. before facing greater generic competition. Bristol-Myers Squibb Company faces similar problems with Plavix set to expire in the not too distant future. Pfizer Inc. and Bristol-Myers Squibb Co. reports are accessible for free by registering today at or

In other pharmaceutical news, Japan temporarily stopped using vaccines from Pfizer Inc. and Sanofi-Aventis SA until it completes an investigation of the deaths of 4 inoculated children. Both companies are cooperating fully and have long established safety records for both vaccines in question. 

Moving forward, pharmaceutical companies will face major obstacles this year with so many drugs facing generic competition. The New York Times reported that more than 10 medications with nearly $50 billion in sales would expire in 2010.

The two drug manufacturers - major stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information